throbber
Case 1:22-cv-01040-CFC Document 101 Filed 05/23/23 Page 1 of 37 PageID #: 3385
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`)))))
`
`)))))))))))
`
`))))))))))
`
`IN RE: OZEMPIC (SEMAGLUTIDE)
`PATENT LITIGATION
`
`NOVO NORDISK INC. and
`NOVO NORDISK A/S,
`
`Plaintiffs,
`
`v.
`
`RIO BIOPHARMACEUTICALS INC.,
`et al.,
`
`Defendants.
`NOVO NORDISK INC. and
`NOVO NORDISK A/S,
`
`Plaintiffs,
`
`v.
`
`MYLAN PHARMACEUTICALS INC.
`
`MDL NO. 22-MD-3038 (CFC)
`ANDA CASE
`
`C.A. No. 22-294 (CFC)
`CONSOLIDATED
`ANDA CASE
`
`C.A. No. 22-1040 (CFC)
`ANDA CASE
`
`Defendant.
`AMENDED JOINT CLAIM CONSTRUCTION CHART
`Pursuant to Section 21 of the Scheduling Order governing this Action (see
`
`D.I. 22; see also D.I. 53 in C.A. No. 22-1040-CFC, adopting the Scheduling
`
`Order entered in C.A. No. 22-294-CFC as D.I. 22), the parties respectfully submit
`
`the attached Amended Joint Claim Construction Chart, addressing the claim
`
`Novo Nordisk Exhibit 2003
`Mylan Pharms. Inc.v. Novo Nordisk A/S
`IPR2023-00724
`Page 00001
`
`

`

`Case 1:22-cv-01040-CFC Document 101 Filed 05/23/23 Page 30 of 37 PageID #: 3414
`
`component
`having a thread
`or spline for
`engaging the
`limiter, and that
`during dose
`setting transfers
`rotational torque
`from one
`component to
`another
`component.”
`
`Term
`No.
`
`Term or Phrase for
`Construction
`
`CLAIM TERMS AT ISSUE IN THE ’462 PATENT
`Claim(s)
`Novo Nordisk’s
`Novo Nordisk’s
`Proposed
`Intrinsic Evidence
`Construction
`Citations
`
`Defendants’
`Proposed
`Construction
`
`14
`
`“A method for
`treating type 2
`diabetes”
`
`1
`
`The phrase is an
`express
`limitation of
`claims 1-10, and
`it carries its plain
`and ordinary
`meaning.
`
`Original
`Proposal: “a
`
`’462 Patent
`Specification:
`- Abstract
`- Figs. 1-3
`- Col.1, ll.17-18
`- Col.1, ll.31-36
`- Col.1, ll.45-50
`- Col.1, ll.56-62
`- Col.2, ll.6-33
`- Col.2, l.51 -
`
`The preambles
`are non-limiting.
`
`To the extent the
`term is a
`limitation, the
`term means
`administering
`semaglutide to
`alleviate the
`
`30
`
`Defendants’
`Intrinsic
`Evidence
`Citations
`’462 patent at
`1:31-2:2;
`5:16-31
`
`1:29-32; 1:45-
`49; 1:56-60;
`2:51-55; 2:63-
`66; 3:3-18;
`4:7-16; 4:25-
`34; 5:16-17;
`
`Novo Nordisk Exhibit 2003
`Mylan Pharms. Inc.v. Novo Nordisk A/S
`IPR2023-00724
`Page 00002
`
`

`

`Case 1:22-cv-01040-CFC Document 101 Filed 05/23/23 Page 31 of 37 PageID #: 3415
`
`Term
`No.
`
`Term or Phrase for
`Construction
`
`CLAIM TERMS AT ISSUE IN THE ’462 PATENT
`Claim(s)
`Novo Nordisk’s
`Novo Nordisk’s
`Proposed
`Intrinsic Evidence
`Construction
`Citations
`
`Defendants’
`Proposed
`Construction
`
`method of caring
`for or managing
`the care of a
`patient so as to
`combat type 2
`diabetes”
`
`Compromise
`Proposal
`Offered During
`Meet and
`Confer Process:
`“A method for
`treating type 2
`diabetes” is a
`limitation, and
`the preamble
`means “the
`claimed
`administration is
`for the care or
`management of a
`patient with type
`
`Col.3, l.5
`- Col.3, ll.4-5
`- Col.3, ll.8-18
`- Col.3, ll. 19-28
`- Col.4, ll.7-14
`- Col.4, ll.25-32
`- Col.4, l.62-
`Col.5, l.49
`- Col.6, ll.2-16
`- Col.6, ll.17-19
`- Col.6, ll.24-28
`- Col.6, ll.29-36
`- Col.6, ll.51-60
`- Col.6, ll.65-66
`- Col.7, ll.27-30
`- Col.8, ll.57-59
`- Col.9, ll.40-42
`- Col.9, ll.52-55
`- Col.10, ll.9-11
`- Col.15, ll.13-14
`- Col.16, ll.58-64
`- Col.17, ll.4-6
`- Col.20, ll.17-22
`
`symptoms and
`complications,
`and/or to cure or
`eliminate or
`prevent, and/or to
`prevent the onset
`of symptoms
`associated with
`type 2 diabetes.
`
`Compromise
`Proposal
`Offered During
`Meet and
`Confer Process:
`“A method for
`treating type 2
`diabetes” is a
`limitation only as
`to the stated
`purpose of the
`claim, and
`imparts no
`
`31
`
`Defendants’
`Intrinsic
`Evidence
`Citations
`6:1-16; 6:29-
`36; 16:56-64;
`17:4-6; 20:17-
`22; 20:31-37;
`20:55-23:26;
`23:26-28:36;
`35:40-36:53
`
`See generally
`’462 patent
`specification
`
`Prosecution
`history of the
`’462 patent at
`specification
`and claims as
`filed, on
`7/21/2017;
`Office action
`of 7/23/2018,
`at 3-8; Office
`action
`
`Novo Nordisk Exhibit 2003
`Mylan Pharms. Inc.v. Novo Nordisk A/S
`IPR2023-00724
`Page 00003
`
`

`

`Case 1:22-cv-01040-CFC Document 101 Filed 05/23/23 Page 32 of 37 PageID #: 3416
`
`Term
`No.
`
`Term or Phrase for
`Construction
`
`CLAIM TERMS AT ISSUE IN THE ’462 PATENT
`Claim(s)
`Novo Nordisk’s
`Novo Nordisk’s
`Proposed
`Intrinsic Evidence
`Construction
`Citations
`
`Defendants’
`Proposed
`Construction
`
`2 diabetes”9
`
`- Col.20, ll.31-37
`- Col.20, ll.49-51
`- Col.20, l.62 –
`Col.21, l.5
`- Col.21, ll.20-29
`- Col.21, ll.31-33
`- Col.22, ll.2-26
`- Table 1
`- Col.23, ll.18-26
`- Col.25, ll.37-42
`
`efficacy. The
`preamble means
`that ‘the claimed
`administration is
`intended as part
`of the care or
`management of a
`patient with type
`2 diabetes but
`does not require
`that the
`administration be
`efficacious in the
`treatment of such
`patient’s type 2
`diabetes.’”10
`
`Defendants’
`Intrinsic
`Evidence
`Citations
`response dated
`1/23/2019, at
`2-4; Notice of
`allowance
`dated
`3/6/2019, at 4-
`5.
`
`9 In advocating for their compromise proposal on this term, Defendants misstate Plaintiffs’ position on this term. In
`Reply, Plaintiffs stated that “Novo Nordisk’s proposed construction [of the preamble] does not include an efficacy
`requirement as Defendants incorrectly argue.” Jt. Br. (D.I. 136) at 24-25 (emphasis added).
`10 Defendants’ proposed construction of the preamble of the ’462 patent adopts Plaintiffs’ position that the preamble
`“does not impart an efficacy requirement.” Jt. Brief (D.I. 119) at 25.
`
`32
`
`Novo Nordisk Exhibit 2003
`Mylan Pharms. Inc.v. Novo Nordisk A/S
`IPR2023-00724
`Page 00004
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket